The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earnings (11.6x vs 5-year average 25.1x) indicate it is attractively priced. Despite facing intense competition from Eli Lilly in the GLP-1 weight-loss drug market and being in a transition period with new oral GLP-1 pills and a volume-driven pricing strategy, the risk/reward balance is seen as leaning towards reward, making the stock 'too cheap to ignore'.